IHE News and Press, iShares U.S. Pharmaceutical From 01/08/24

2024-01-08 12:53:29 ET Summary Large pharma stocks, including Johnson & Johnson, may be experiencing a shift in favor as investors move away from glamour growth stocks as 2024 gets underway. Johnson & Johnson is a leading global healthcare company with a below-market valua...

2024-01-08 08:31:52 ET Summary The healthcare sector was flat in 2023 year as a result of some unique issues. Drug price regulation will be a serious challenge for the sector this year. Defensive healthcare industry groups should do well during the first half and biotechnology...

2024-01-07 04:45:00 ET Summary Suzhou Ribo Life Science formed a collaboration with Boehringer Ingelheim in a deal that could be worth up to $2 billion. Suzhou MediLink Therapeutics out-licensed global rights for its pre-clinical c-Mesenchymal epithelial transition factor ADC to R...

2024-01-06 08:15:00 ET Summary Global equity markets experienced a surge in 2023 driven by economic growth and investor confidence. US equity returns exceeded expectations despite concerns about higher rates, inflation, and geopolitical tension. In 2024, investors should focus...

2023-12-21 14:50:28 ET More on iShares U.S. Pharmaceuticals ETF IHE: You Better Like Eli Lilly And Johnson & Johnson To Buy This Seeking Alpha’s Quant Rating on iShares U.S. Pharmaceuticals ETF Dividend scorecard for iShares U.S. Pharmaceuticals ETF ...

BlackRock, Inc. (NYSE: BLK) today announced its plans to implement stock splits for the ETFs listed below. These splits will lower the share price and increase the number of outstanding shares. The total value of shares outstanding is not affected by the share split. For the iShares Core S&am...

2023-12-21 08:25:00 ET Summary Given strong recent market returns and another wave of capital inflows, the backdrop is probably not enough to lead to strong tactical performance from risk assets. The US has a more favorable demographic trend; its working-age population is expected...

2023-12-20 06:19:00 ET Summary Can the Magnificent 7 continue to rally into 2024? How the Magnificent 7's rise compares to the dot-com bubble. Why the rise in tech stocks highlights shortcomings for the markets. The rise of the Magnificent 7 tech stocks has been a ke...

2023-12-14 05:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-12-09 03:00:00 ET Summary The global markets experienced high volatility in 2023 due to factors such as high interest rates, bank failures, and a surge in bond yields. The macro environment in 2024 is expected to be complex and interesting, with rewards for investors who are ...